ProMIS Neurosciences Holds Shareholder Meeting

TL;DR

ProMIS Neurosciences shareholders met June 13th to vote on directors and auditors.

AI Summary

On June 13, 2024, ProMIS Neurosciences Inc. filed an 8-K report to announce the results of its annual and special meeting of shareholders. The company's shareholders voted on several matters, including the election of directors and the appointment of auditors.

Why It Matters

Shareholder meetings are crucial for corporate governance, allowing investors to influence company direction and hold management accountable.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure regarding a shareholder meeting and does not involve significant financial or operational changes.

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant
• June 13, 2024 (date) — Date of earliest event reported
• 416-847-6898 (phone_number) — Registrant's telephone number
• Toronto, Ontario (location) — Principal executive offices

FAQ

Filing Documents

• pmn-20240613x8k.htm (8-K) — 65KB
• 0001558370-24-009202.txt ( ) — 224KB
• pmn-20240613.xsd (EX-101.SCH) — 4KB
• pmn-20240613_def.xml (EX-101.DEF) — 3KB
• pmn-20240613_lab.xml (EX-101.LAB) — 13KB
• pmn-20240613_pre.xml (EX-101.PRE) — 12KB
• pmn-20240613x8k_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 13, 2024, ProMIS Neurosciences Inc. (the " Company ") held its 2024 annual meeting of shareholders (the " Annual Meeting "). The shareholders considered four proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 25, 2024. Of the 18,961,116 Common Shares, no par value per share (the " Common Shares "), outstanding as of the record date, 7,811,371 Common Shares hares, or approximately 41.19%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of shareholders at the Annual Meeting. Proposal No. 1 : Election of seven nominees to serve as directors until the 2025 annual meeting of shareholders or until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal. The votes were cast as follows by holders of Common Shares: Name Votes For Votes Withheld Eugene Williams 4,149,424 515,817 Neil Cashman, M.D. 4,605,556 59,685 Patrick D. Kirwin 4,524,061 141,180 Joshua Mandel-Brehm 4,491,624 173,617 Maggie Shafmaster, Ph.D,J.D. 4,493,208 172,033 Neil K. Warma 4,399,117 266,124 William Wyman 4,018,983 646,258 Broker Non-Votes: 3,228,732 All seven nominees were elected. Proposal No. 2: A special resolution authorizing the directors of the Company to set the number of directors of the Company for the ensuing year at seven directors and authorizing the directors of the Company to set the number of directors within the maximum and minimum numbers provided for in the articles of the Company by way of resolution from time to time. Votes For Votes Against Abstained Authorization to set the number of directors of the Corporation at seven and to set the number of directors within the minimum and maximum numbers provided in the articles by way of a resolutio

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: June 14, 2024 By: /s/ Neil Warma Name: Neil Warma Title: Interim Chief Executive Officer